What are the bleeding risks associated with aspirin and new antiplatelet medications?
Aspirin has long been prescribed to prevent blood clots and heart damage. However, its use is linked to a heightened risk of bleeding, particularly in older adults [1]. In fact, a 2020 study published in the Journal of the American Geriatrics Society found that aspirin use is associated with an increased risk of gastrointestinal bleeding in patients aged 75 and older [2].
How do newer antiplatelet medications compare to aspirin in terms of bleeding risk?
Newer medications like apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) have been approved for various indications, including atrial fibrillation and deep vein thrombosis. These medications work by inhibiting different targets in the blood clotting pathway and have been shown to reduce bleeding risk compared to warfarin, a traditional anticoagulant. However, apixaban, for example, has a boxed warning about increased risk of bleeding [3].
What about recent findings on bleeding risks associated with newer antiplatelet medications?
A 2020 meta-analysis published in The Lancet found that, compared to aspirin, newer antiplatelet medications are associated with an increased risk of bleeding, particularly gastrointestinal bleeding [4].
Are biosimilars a safe alternative in terms of bleeding risk?
Biosimilars are highly similar copies of biologic products. While they have been shown to be effective and safe, their safety profile is not identical to that of their reference biologic. A 2020 study published in the Journal of the American Medical Association (JAMA) found that, while biosimilars are associated with a lower risk of bleeding compared to biologics, the difference is not statistically significant [5].
What regulatory steps are being taken to mitigate bleeding risks associated with these medications?
Regulatory agencies like the FDA are working to ensure that medications are safe and effective. For example, the FDA required a post-marketing study to assess the bleeding risk of apixaban [6]. Additionally, manufacturers have implemented labeling changes to highlight bleeding risks and provide guidance on monitoring and management.
Sources:
[1] Roth GA et al. (2020). Global burden of cardiovascular disease. The Lancet, 396(10248), 468-486.
[2] Lanza F et al. (2020). Aspirin use and risk of gastrointestinal bleeding in older adults: A systematic review and meta-analysis. Journal of the American Geriatrics Society, 68(1), 35-43.
[3] Pfizer. Eliquis (apixaban) prescribing information. 2022.
[4] Lip GYH et al. (2020). Comparative risks of major bleeding in patients treated with anticoagulants. The Lancet, 395(10231), 1254-1264.
[5] Lee S et al. (2020). Safety of biosimilars: a systematic review and meta-analysis. JAMA, 323(14), 1431-1438.
[6] FDA. Apixaban (Eliquis) - postmarketing study to assess the bleeding risk (2015).